我要投票 CONBA康恩贝在中草药行业中的票数:132
· 外 推 电 报 ·
2025-02-05 18:49:30 星期三

【CONBA康恩贝是哪个国家的品牌?】

CONBA康恩贝是什么牌子?「CONBA康恩贝」是 浙江康恩贝制药股份有限公司 旗下著名品牌。该品牌发源于浙江,由创始人胡季强在1993-01-09期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

浙江康恩贝制药股份有限公司是康恩贝集团有限公司的控股子公司,前身为创建于1969年的“兰溪云山制药厂”,经过三十余年发展,现已成长为一家实施全产业链经营,集药材种植、提取、研发、生产、销售于一体的大型医药上市企业。至2015年底,公司有员工近万名,注册资本167,382万元。公司于2004年4月在上海证券交易所上市,股票代码为600572。

公司注册地为浙江省兰溪市,管理总部设在浙江省杭州市,产业布局涵盖浙江的杭州、金华、兰溪,以及江西、云南、内蒙古、四川、贵州、黑龙江等地。公司旗下拥有浙江康恩贝中药有限公司、浙江金华康恩贝生物制药有限公司、云南希陶绿色药业股份有限公司、江西天施康中药股份有限公司、浙江康恩贝医药销售有限公司、杭州康恩贝制药有限公司、上海康恩贝医药有限公司、浙江康恩贝药品研究开发有限公司、内蒙古康恩贝药业有限公司、贵州拜特制药有限公司、浙江珍诚医药在线股份有限公司等多个颇具规模和实力的全资及控股子公司。

公司为国家火炬计划重点高新技术企业、国家创新型企业、国家中药五十强企业、浙江省“五个一批”重点骨干企业、浙江省专利示范企业、国家中药现代化科技产业(浙江)基地示范企业、首批国家知识产权优势企业。经过多年来的技术创新与提升,公司在心脑血管系统用药、泌尿系统用药、抗糖尿病用药、呼吸道系统用药、消化系统用药和抗感染药等药物的研发,以及植物提取分离和结构改造、新型药物释放系统应用等诸多方面积累了诸多的优势。

公司历来十分重视产品品牌和企业品牌的培育和保护,在泌尿系统及心脑血管系统等多个领域建立了消费者熟知与认可的品牌,“康恩贝”、“前列康”、“珍视明”、“天保宁”、“阿乐欣”、“金康”、“金奥康”、“希陶”、“天保康”、“天狮”、“恤彤”等均在各自领域内独放异彩,相比同类竞争产品展现了较为突出的品牌优势,承载着用户的由衷认可。

近年来,公司以“内生增长+投资并购”双轮驱动为发展策略,积极推进内部资源的整合,完善营销网络建设,扎实推进研发、质量体系及企业文化的提升,坚定布局医药电商业务,各项工作取得了良好的进展与成果。

展望未来,公司将继续秉承“为员工幸福尽全心全力为人类健康献至诚至爱”的企业使命,恪守“诚实守信、依法经营、质量第一、用户至上、保障安全、友好环境、幸福员工、奉献社会”八大治企基石,以现代中药和植物药产业为核心,发展化学制药、生物制药业务,同时通过产业互联网+与创新,向药业产业链上游(药材种植加工)和下游(医疗与健康服务)拓展延伸,努力建立基于互联网和全产业链的大健康产业生态!

英文翻译:Zhejiang Kangenbei Pharmaceutical Co., Ltd. is the holding subsidiary of Kangenbei Group Co., Ltd., formerly known as "Lanxi Yunshan pharmaceutical factory" founded in 1969. After more than 30 years of development, it has grown into a large pharmaceutical listed enterprise that implements the whole industrial chain operation and integrates the cultivation, extraction, research and development, production and sales of medicinal materials. By the end of 2015, the company had nearly 10000 employees with a registered capital of 1673.82 million yuan. The company was listed on Shanghai Stock Exchange in April 2004 with stock code of 600572. The company is registered in Lanxi City, Zhejiang Province, with its management headquarters in Hangzhou City, Zhejiang Province. Its industrial layout covers Hangzhou, Jinhua, Lanxi, Jiangxi, Yunnan, Inner Mongolia, Sichuan, Guizhou, Heilongjiang, etc. The company has Zhejiang kangenbe traditional Chinese Medicine Co., Ltd., Zhejiang Jinhua kangenbe Biological Pharmaceutical Co., Ltd., Yunnan Xitao green Pharmaceutical Co., Ltd., Jiangxi tianshikang traditional Chinese Medicine Co., Ltd., Zhejiang kangenbe Pharmaceutical Sales Co., Ltd., Hangzhou kangenbe Pharmaceutical Co., Ltd., Shanghai kangenbe Pharmaceutical Co., Ltd., Zhejiang kangenbe pharmaceutical research and Development Co., Ltd , Inner Mongolia Kangenbei Pharmaceutical Co., Ltd., Guizhou Beite Pharmaceutical Co., Ltd., Zhejiang Zhencheng pharmaceutical online Co., Ltd. and other large-scale and powerful wholly-owned and holding subsidiaries. The company is a key high-tech enterprise of national torch plan, a national innovative enterprise, a top 50 enterprise of national traditional Chinese medicine, a key backbone enterprise of "five in one batch" in Zhejiang Province, a patent demonstration enterprise in Zhejiang Province, a demonstration enterprise of national modern science and technology industry (Zhejiang) base of traditional Chinese medicine, and the first batch of national intellectual property advantage enterprises. After years of technological innovation and upgrading, the company has accumulated many advantages in the research and development of cardiovascular and cerebrovascular system drugs, urinary system drugs, anti diabetes drugs, respiratory system drugs, digestive system drugs and anti infective drugs, as well as plant extraction and separation and structural transformation, new drug release system applications and many other aspects. The company has always attached great importance to the cultivation and protection of product brands and enterprise brands. It has established brands well known and recognized by consumers in various fields such as urinary system, cardio cerebrovascular system, etc., "Kangenbei", "QianLieKang", "Zhenshiming", "Tianbaoning", "alexin", "Jinkang", "jinaokang", "Xitao", "Tianbaokang", "Tianshi", "Xiangtong" ”All of them are unique in their respective fields. Compared with similar competitive products, they show more prominent brand advantages and bear the sincere recognition of users. In recent years, the company has taken "endogenous growth + investment merger and acquisition" as its development strategy, actively promoted the integration of internal resources, improved the construction of marketing network, solidly promoted the improvement of R & D, quality system and corporate culture, firmly arranged the pharmaceutical e-commerce business, and made good progress and achievements in various works. Looking forward to the future, the company will continue to uphold the corporate mission of "do our best for the well-being of our employees and the best for human health", adhere to the eight corporate cornerstones of "honesty and trustworthiness, operation according to law, quality first, user first, security, environment-friendly, happy employees, and dedication to the society", and develop chemical pharmacy and biopharmaceutical industry with modern Chinese medicine and plant medicine industry as the core Meanwhile, the industry will expand to the upstream of the pharmaceutical industry chain (medicinal plant processing) and downstream (medical and health services) through the Internet plus and innovation, and strive to build a healthy industrial ecosystem based on the Internet and the whole industry chain.

本文链接: https://www.waitui.com/brand/ac7af194f.html 联系电话:057187774811

千城特选小程序码

7×24h 快讯

慈星股份:终止筹划购买武汉敏声控股权并配套募资事项,股票明起复牌

36氪获悉,慈星股份公告,公司因筹划发行股份及支付现金购买武汉敏声新技术有限公司控股权并募集配套资金事项,公司股票自2025年1月15日开市时起开始停牌。经交易相关方商讨研究决定终止筹划本次交易事项,公司股票将于2025年2月6日(星期四)开市起复牌。 截至公告日,交易各方未就本次交易具体方案、交易条件达成最终实质性协议。

50分钟前

汇丰控股:昨日耗资约1.76亿港元回购219.76万股公司股份

36氪获悉,汇丰控股公告,公司于2月4日耗资约1.76亿港元回购219.76万股公司股份,每股回购价格79.6港元-80.45港元。

50分钟前

印尼网约车巨头GoTo否认与Grab合并传闻

印尼网约车巨头GoTo当地时间2月4日提交文件,否认同竞争对手Grab的合并传闻。该公司称,“除实施股票回购外,未来12个月内没有任何重大行动计划”。此前有市场消息称,Grab与GoTo最近几周加快协商,认为今年是达成交易的有利时机。两家公司上市后均逐渐朝向取得盈利迈进,但竞争激烈导致价格无法调涨,同时挤压利润空间。据报道,过去几年双方一直在断断续续地协商,合并障碍包括双方之间的分歧,以及两家公司在印尼、新加坡等市场主导地位可能带来的反垄断问题。(界面)

50分钟前

众鑫股份:泰国工厂一车间正式投产,预计2025年完成产量3万吨以上

36氪获悉,众鑫股份公告,公司泰国工厂一车间已顺利安装完毕,并于2025年1月8号开始调试设备并试机生产,2月1日顺利完成试机并正式投产。同时,二车间开始安装设备。公司预计2025年完成产量3万吨以上,2026年完成产量5万吨。此外,公司将根据国际市场的变化情况,决策是否对泰国工厂实施扩产计划。本次试机成功为公司拓展海外业务打下了基础,也验证了新装备的先进性,为今后的装备研发与升级提供了宝贵经验。

50分钟前

杭州银行:2024年净利润169.83亿元,同比增长18.08%

36氪获悉, 杭州银行发布业绩快报,2024年度实现营业收入383.81亿元,同比增长9.61%;归属于上市公司股东的净利润169.83亿元,同比增长18.08%。截至2024年末,公司总资产21125.91亿元,较上年末增长14.73%;贷款总额9374.99亿元,较上年末增长16.16%;存款总额12725.51亿元,较上年末增长21.74%。

50分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询